Chimerix, Inc. (CMRX)

NASDAQ: CMRX · IEX Real-Time Price · USD
5.77 0.15 (2.67%)
Jan 19, 2022 9:30 AM EST - Market open
Market Cap501.20M
Revenue (ttm)3.05M
Net Income (ttm)-145.41M
Shares Out86.86M
EPS (ttm)-1.84
PE Ration/a
Forward PE227.27
Dividendn/a
Ex-Dividend Daten/a
Volume38,342
Open5.92
Previous Close5.62
Day's Range5.77 - 5.77
52-Week Range4.75 - 11.57
Beta1.36
AnalystsStrong Buy
Price Target18.67 (+223.6%)
Earnings DateNov 4, 2021

About CMRX

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 ...

IndustryBiotechnology
IPO DateApr 11, 2013
CEOMichael Sherman
Employees54
Stock ExchangeNASDAQ
Ticker SymbolCMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Chimerix stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 223.57% from the latest price.

Price Target
$18.67
(223.57% upside)
Analyst Consensus: Strong Buy

News

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer...

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

17 hours ago - GlobeNewsWire

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

2 weeks ago - GlobeNewsWire

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Soc...

– Plenary Session Presentation on Saturday, November 20 –

2 months ago - GlobeNewsWire

Chimerix to Present at Jefferies London Healthcare Conference

DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fac...

2 months ago - GlobeNewsWire

Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

2 months ago - GlobeNewsWire

Chimerix Shares Brain Cancer Trial Data

Chimerix Inc (NASDAQ: CMRX) has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer).  ONC201 is an orally admin...

2 months ago - Benzinga

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update

– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –

2 months ago - GlobeNewsWire

Analysts Estimate Chimerix (CMRX) to Report a Decline in Earnings: What to Look Out for

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021

DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their ...

2 months ago - GlobeNewsWire

Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

4 months ago - GlobeNewsWire

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

5 months ago - GlobeNewsWire

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

5 months ago - GlobeNewsWire

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and pa...

7 months ago - GlobeNewsWire

Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today ...

7 months ago - GlobeNewsWire

Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –

8 months ago - GlobeNewsWire

Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?

Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon

8 months ago - Zacks Investment Research

Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021

DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

8 months ago - GlobeNewsWire

Chimerix Appoints Vicki Vakiener to Board of Directors

DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

8 months ago - GlobeNewsWire

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

9 months ago - GlobeNewsWire

Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

10 months ago - GlobeNewsWire

Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Re...

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung disease...

10 months ago - PRNewsWire

Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study

Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The...

10 months ago - Benzinga

Steven Cohen Dives Into Chimerix

Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.

10 months ago - GuruFocus

Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

11 months ago - GlobeNewsWire